Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.50 |
| ▸ | PDE4A | P27815 | 2/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | TOP2A | P11388 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31216608 | 1.00 | GPR119 (0.64) | GPR119ALDH1A1LMNAMAPTPDE4D | |
| SCHEMBL31216598 | 1.00 | GPR119 (0.64) | GPR119ALDH1A1LMNAMAPTPDE4D | |
| SCHEMBL30140271 | 0.94 | GPR119 (0.57) | GPR119ALDH1A1LMNAMAPTPDE4D | |
| SCHEMBL13419621 | 0.94 | GPR119 (0.57) | GPR119ALDH1A1LMNAMAPTPDE4D | |
| SCHEMBL12002916 | 0.89 | GPR119 (0.51) | GPR119ALDH1A1LMNAMAPTPDE4D | |
| SCHEMBL4465377 | 0.88 | ALDH1A1 (0.54) | GPR119ALDH1A1LMNAMAPTPDE4D | |
| SCHEMBL13419624 | 0.88 | GPR119 (0.51) | GPR119ALDH1A1LMNAMAPTPDE4B | |
| SCHEMBL5864921 | 0.88 | GPR119 (0.52) | GPR119ALDH1A1LMNAMAPTPDE4D | |
| SCHEMBL5970747 | 0.87 | ALDH1A1 (0.53) | GPR119ALDH1A1LMNAMAPTPDE4D | |
| SCHEMBL5864756 | 0.87 | ALDH1A1 (0.53) | GPR119ALDH1A1LMNAMAPTPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024208256-A1 | TARGETED PROTEIN DEGRADATION COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海汇伦医药股份有限公司 | 2024-10-10 | — | — | WO | disclosed |
| US-20110190280-A1 | Thiazole And Oxazole Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2011-08-04 | — | — | US | disclosed |
| US-20110190280-A1 | Thiazole And Oxazole Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2011-08-04 | — | — | US | disclosed |
| EP-2197876-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | Glaxosmithkline LLC (US) | 2010-06-23 | — | — | EP | disclosed |
| US-7671058-B2 | N-(3,4-disubstituted phenyl) salicylamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-03-02 | — | — | US | disclosed |
| US-7671058-B2 | N-(3,4-disubstituted phenyl) salicylamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-03-02 | — | — | US | disclosed |
| WO-2009032667-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032667-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| US-20080227784-A1 | N-(3,4-disubstituted phenyl) salicylamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-09-18 | — | — | US | disclosed |
| US-20080227784-A1 | N-(3,4-disubstituted phenyl) salicylamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-09-18 | — | — | US | disclosed |
| EP-1245564-B1 | BENZAMIDINE DERIVATIVES | SANKYO CO (JP) | 2006-04-05 | — | — | EP | disclosed |
| US-20040248981-A1 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-12-09 | — | — | US | disclosed |
| US-20040010009-A1 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-15 | — | — | US | disclosed |
| US-6555556-B1 | N-(4-(1-acetimidoylpiperidin-4-yl)oxyphenyl)-N-((E)-3-(3 -amidinophenyl)-2-methyl-2-propenyl)sulfamoylacetic acid dihydrochloride for example; factor Xa inhibitors | SANKYO COMPANY, LIMITED (JP) | 2003-04-29 | — | — | US | disclosed |
| EP-1245564-A1 | BENZAMIDINE DERIVATIVES | Sankyo Company, Limited (JP) | 2002-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190280-A1 | Thiazole And Oxazole Kinase Inhibitors | PDXK, MAP3K1, MAP4K2 | GPR119 676/4885ALDH1A1 3014/4885LMNA 3516/4885 |
| US-20040010009-A1 | Benzamidine derivatives | HABP2, F7, F2 | GPR119 3838/4885ALDH1A1 1918/4885LMNA 1709/4885 |
| US-20080227784-A1 | N-(3,4-disubstituted phenyl) salicylamide derivatives | STAT6, RELA, NFKB2 | GPR119 2582/4885ALDH1A1 2263/4885LMNA 2990/4885 |
| US-20040248981-A1 | Benzamidine derivatives | HABP2, F7, F2 | GPR119 3852/4885ALDH1A1 1987/4885LMNA 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.